Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Fuji
QuintilesIMS
Daiichi Sankyo
Novartis
Chubb
Baxter
Moodys
Deloitte
Johnson and Johnson

Generated: October 20, 2017

DrugPatentWatch Database Preview

ZOLPIMIST Drug Profile

« Back to Dashboard

What is the patent landscape for Zolpimist, and what generic Zolpimist alternatives are available?

Zolpimist is a drug marketed by Magna Pharms and is included in one NDA. There are two patents protecting this drug.

This drug has eighty-eight patent family members in ten countries and four supplementary protection certificates in four countries.

The generic ingredient in ZOLPIMIST is zolpidem tartrate. There are thirty-one drug master file entries for this compound. Sixty-six suppliers are listed for this compound. Additional details are available on the zolpidem tartrate profile page.

Summary for Tradename: ZOLPIMIST

US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ZOLPIMIST at DailyMed

Pharmacology for Tradename: ZOLPIMIST

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Magna Pharms
ZOLPIMIST
zolpidem tartrate
SPRAY, METERED;ORAL022196-001Dec 19, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
Magna Pharms
ZOLPIMIST
zolpidem tartrate
SPRAY, METERED;ORAL022196-001Dec 19, 2008RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZOLPIMIST

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Magna Pharms
ZOLPIMIST
zolpidem tartrate
SPRAY, METERED;ORAL022196-001Dec 19, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: ZOLPIMIST

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
► Subscribe
ZOLPIMIST
► Subscribe

Non-Orange Book Patents for Tradename: ZOLPIMIST

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,078,816Buccal, polar and non-polar spray containing ondansetron► Subscribe
6,676,931 Buccal, polar and non-polar spray or capsule► Subscribe
6,977,070 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system► Subscribe
6,998,110Buccal, polar and non-polar spray or capsule► Subscribe
6,969,508 Buccal, polar and non-polar spray or capsule containing drugs for treating pain► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ZOLPIMIST

Country Document Number Estimated Expiration
Canada2497114► Subscribe
European Patent Office2277506► Subscribe
World Intellectual Property Organization (WIPO)2005032517► Subscribe
World Intellectual Property Organization (WIPO)2005032519► Subscribe
European Patent Office1549290► Subscribe
European Patent Office2283815► Subscribe
Japan2010241843► Subscribe
Australia2003272242► Subscribe
South Korea20060120065► Subscribe
World Intellectual Property Organization (WIPO)2004043428► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ZOLPIMIST

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00714Netherlands► SubscribePRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718
2015000006Germany► SubscribePRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718
636Luxembourg► SubscribePRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
2015 00004Denmark► SubscribePRODUCT NAME: ZOLPIDEM OG FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER ZOLPIDEMTARTRAT; NAT. REG. NO/DATE: 47607 OG 47608 20120719; FIRST REG. NO/DATE: (B BE424286 OG BE424295 20120718
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Argus Health
Chubb
Boehringer Ingelheim
Fuji
Teva
Mallinckrodt
Express Scripts
Queensland Health
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot